Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

R&D In Brief: Amgen, Arrowhead, Rigel, Coherus, Achillion

Executive Summary

Arrowhead readies to advance its RNAi candidate for hepatitis B, while data on Achillion’s ‘3102 plus Sovaldi prepare the firm to start trials of its proprietary HCV combo. Coherus advances with a Humira biosimilar and Amgen will file Kyprolis for new indication despite failed study, while Rigel dry-eye failure has the firm refocusing on fostamatinib.

Advertisement
Advertisement

Related Content

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS056325

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel